Atossa Therapeutics ATOS

NASDAQ ATOS

$2.40 -0.12 (-4.57%)

At close: Sep 9, 2026 · 4:00 PM EDT

Key Stats

Market Cap21.82 Mn

P/E-0.72

Div. Yield0.00

Add ratio to table…

About

Atossa Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing proprietary medicines for oncology with an emphasis on breast cancer and related breast conditions. The company’s lead drug candidate is Z endoxifen an oral small molecule that acts as both a selective estrogen receptor modulator and a selective estrogen receptor degrader. Unlike tamoxifen Z endoxifen does not require CYP2D6 mediated first pass metabolism to reach therapeutic levels which reduces variability in patient response. Atossa holds a broad patent portfolio covering Z endoxifen with protection projected to last at least until November 17 2038. Beyond breast cancer the firm is investigating Z endoxifen in rare disease settings such as Duchenne muscular dystrophy carriers of the dystrophin gene and McCune Albright Syndrome. The company has developed a proprietary manufacturing process for the active pharmaceutical ingredient and drug product that includes multiple dosage strengths and qualified suppliers.

The company does not currently generate revenue from product sales because it remains in the research and development phase and has not yet commercialized any therapeutic candidates. Its financial resources are derived from equity offerings warrant exercises and other financing activities to support ongoing clinical studies and operational expenses. As of December 31 2025 Atossa reported cash and cash equivalents of approximately forty one point three million dollars. The firm has entered into an at the market offering agreement that allows it to sell up to fifty million dollars of common stock through a sales agent if additional capital is needed. Management states that it expects existing resources to fund planned operations for the next twelve months but will require further financing to sustain activities beyond that period.

Atossa Therapeutics, Inc. occupies a niche within the oncology sector by advancing Z endoxifen a more potent metabolite of tamoxifen that does not require CYP2D6 mediated activation thereby reducing variability in patient response. The molecule functions as both a selective estrogen receptor modulator and a selective estrogen receptor degrader offering dual mechanism of action that may overcome resistance seen with standard endocrine therapies. Competitors in the breast cancer space include established SERMs such as tamoxifen and raloxifene aromatase inhibitors like letrozole and anastrozole and CDK4/6 inhibitors such as palbociclib ribociclib and abemaciclib. Atossa differentiates itself through strong patent protection extending to 2038 orphan drug and rare pediatric disease designations for Duchenne muscular dystrophy and potential similar designations for McCune Albright Syndrome. Early clinical data from the Karisma study showed that low dose Z endoxifen significantly reduced mammographic breast density compared to placebo with a mean reduction of seventeen point three percent for the one milligram dose and twenty three point five percent for the two milligram dose. In the I SPY 2 endocrine optimization pilot Z endoxifen demonstrated median MRI functional tumor volume reduction of approximately seventy two percent and clearance of circulating tumor DNA in a majority of baseline positive patients. These findings suggest tumor shrinkage activity that is atypical for conventional endocrine agents which are generally cytostatic. The company also explores Z endoxifen in gynecological cancers endocrine resistance driven by ESR1 mutations and rare indications such as Duchenne muscular dystrophy where preclinical models indicated muscle protective anti inflammatory and anti fibrotic effects. Market analyses estimate the global ER positive breast cancer treatment market to reach approximately thirty billion dollars by 2030. Atossa believes the potential United States market for Z endoxifen across breast cancer treatment and prevention settings could exceed one billion dollars annually.

The company’s future customers will include patients with estrogen receptor positive breast cancer individuals with rare muscle wasting disorders such as Duchenne muscular dystrophy and carriers of the dystrophin gene women affected by McCune Albright Syndrome and healthcare providers in oncology clinics hospitals and specialized treatment centers who will prescribe and administer its therapeutic candidates upon regulatory approval. In the breast cancer setting patients are typically treated by oncologists surgeons and radiation specialists in community hospitals academic medical centers and dedicated cancer institutes. For rare disease indications the target population includes pediatric patients with Duchenne muscular dystrophy adolescent and adult carriers of the dystrophin gene and young girls diagnosed with McCune Albright Syndrome who receive care from neurologists geneticists endocrinologists and pediatric specialty centers. Atossa anticipates that successful commercialization will involve partnerships with pharmaceutical distributors specialty pharmacy networks and potentially collaborations with larger biopharmaceutical firms for co promotion or co development of its product candidates.

Investment Thesis

▲ Bull case

Atossa Therapeutics' lead candidate (Z)-endoxifen demonstrates robust estrogen receptor inhibition across clinically relevant ESR1 mutations in preclinical data, directly addressing a major mechanism of endocrine resistance in ER+/HER2- breast cancer that remains an unmet medical need despite next-generation therapies. This positions (Z)-endoxifen as a potentially superior therapeutic option for patients who develop resistance to standard endocrine treatments, with the ASCO 2026 abstract acceptance highlighting its clinical relevance and potential to capture significant market share in the resistant breast cancer segment, where current options are limited and costly. The mechanistic evidence showing ligand-independent ER activation blockade suggests (Z)-endoxifen could overcome a key limitation of existing SERDs and SERMs, creating a differentiated value proposition in a multi-billion dollar oncology market.
The EVANGELINE Phase 2 trial evaluating (Z)-endoxifen plus goserelin as neoadjuvant therapy in premenopausal ER+/HER2- breast cancer represents a strategic near-term catalyst, as neoadjuvant settings allow for rapid assessment of pathological complete response (pCR) rates—a strong predictor of long-term survival and a critical endpoint for accelerated approval pathways. Success in this high-risk population could enable breakthrough therapy designation and rapid regulatory advancement, particularly given the unmet need for effective neoadjuvant options in premenopausal women where chemotherapy intolerance limits current standards. The trial's focus on dual ER and PKCβ1/AKT pathway targeting leverages (Z)-endoxifen's unique pharmacology distinct from tamoxifen, potentially offering superior efficacy and tolerability compared to existing endocrine backbones in combination regimens.
Atossa's expansion into rare diseases via (Z)-endoxifen for Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS) presents a significant non-dilutive value driver through FDA Rare Pediatric Disease (RPD) designations, which upon approval could yield Priority Review Vouchers (PRVs) historically valued at $100–$205 million in recent transactions. The accepted review article in Degenerative Neurological and Neuromuscular Disease strengthening the utrophin pathway mechanistic rationale, combined with preclinical data showing restored muscle performance and reduced damage biomarkers in mdx5Cv mice, de-risks the DMD indication and supports progression to clinical trials. This dual-track strategy—oncology for near-term revenue and rare diseases for high-value regulatory incentives—diversifies risk while leveraging the same core asset across multi-billion dollar markets with limited competition.
Recent leadership additions, including Kathy Puyana Theall (ex-Stemline-Menarini, led ORSERDU™ approval) as Medical Director - Breast Oncology and Adebola Giwa (ex-Maze Therapeutics) as Medical Director - Rare Diseases, directly address historical execution risks in clinical development and regulatory strategy. Their proven track records in securing global approvals for novel endocrine therapies and advancing rare disease programs enhance Atossa's ability to navigate complex FDA pathways, accelerate trial enrollment, and position (Z)-endoxifen for successful BLA submissions. This strengthened clinical leadership, combined with a cash runway exceeding one year ($31.7M as of Q1 2026), reduces financing risk and supports disciplined advancement toward key milestones without near-term dilution concerns.

Atossa Therapeutics' lead candidate (Z)-endoxifen demonstrates robust estrogen receptor inhibition across clinically relevant ESR1 mutations in preclinical data, directly addressing a major mechanism of endocrine resistance in ER+/HER2- breast cancer that remains an unmet medical need despite next-generation therapies. This positions (Z)-endoxifen as a potentially superior therapeutic option for patients who develop resistance to standard endocrine treatments, with the ASCO 2026 abstract acceptance highlighting its clinical relevance and potential to capture significant market share in the resistant breast cancer segment, where current options are limited and costly. The mechanistic evidence showing ligand-independent ER activation blockade suggests (Z)-endoxifen could overcome a key limitation of existing SERDs and SERMs, creating a differentiated value proposition in a multi-billion dollar oncology market.
The EVANGELINE Phase 2 trial evaluating (Z)-endoxifen plus goserelin as neoadjuvant therapy in premenopausal ER+/HER2- breast cancer represents a strategic near-term catalyst, as neoadjuvant settings allow for rapid assessment of pathological complete response (pCR) rates—a strong predictor of long-term survival and a critical endpoint for accelerated approval pathways. Success in this high-risk population could enable breakthrough therapy designation and rapid regulatory advancement, particularly given the unmet need for effective neoadjuvant options in premenopausal women where chemotherapy intolerance limits current standards. The trial's focus on dual ER and PKCβ1/AKT pathway targeting leverages (Z)-endoxifen's unique pharmacology distinct from tamoxifen, potentially offering superior efficacy and tolerability compared to existing endocrine backbones in combination regimens.
Atossa's expansion into rare diseases via (Z)-endoxifen for Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS) presents a significant non-dilutive value driver through FDA Rare Pediatric Disease (RPD) designations, which upon approval could yield Priority Review Vouchers (PRVs) historically valued at $100–$205 million in recent transactions. The accepted review article in Degenerative Neurological and Neuromuscular Disease strengthening the utrophin pathway mechanistic rationale, combined with preclinical data showing restored muscle performance and reduced damage biomarkers in mdx5Cv mice, de-risks the DMD indication and supports progression to clinical trials. This dual-track strategy—oncology for near-term revenue and rare diseases for high-value regulatory incentives—diversifies risk while leveraging the same core asset across multi-billion dollar markets with limited competition.
Recent leadership additions, including Kathy Puyana Theall (ex-Stemline-Menarini, led ORSERDU™ approval) as Medical Director - Breast Oncology and Adebola Giwa (ex-Maze Therapeutics) as Medical Director - Rare Diseases, directly address historical execution risks in clinical development and regulatory strategy. Their proven track records in securing global approvals for novel endocrine therapies and advancing rare disease programs enhance Atossa's ability to navigate complex FDA pathways, accelerate trial enrollment, and position (Z)-endoxifen for successful BLA submissions. This strengthened clinical leadership, combined with a cash runway exceeding one year ($31.7M as of Q1 2026), reduces financing risk and supports disciplined advancement toward key milestones without near-term dilution concerns.

▼ Bear case

Despite promising preclinical ESR1 mutation data, Atossa has not disclosed any clinical efficacy results for (Z)-endoxifen in endocrine-resistant breast cancer patients, creating significant uncertainty about translational success from preclinical models to human trials. The lack of updated clinical data from ongoing breast cancer studies (beyond the KARISMA prevention trial) raises concerns about whether the drug can achieve meaningful tumor shrinkage or PFS benefits in actual patients with resistant disease, especially given the high failure rate of endocrine therapies targeting ESR1 mutants. Without Phase 2 efficacy signals in the target resistant population, the bullish thesis relies on mechanistic plausibility rather than clinical proof, leaving the company vulnerable to negative trial outcomes that could invalidate the core oncology value proposition.
The EVANGELINE trial's open-label, single-arm Phase 2 design in neoadjuvant therapy lacks a control group, severely limiting the ability to attribute observed biological effects to (Z)-endoxifen plus goserelin versus natural history or placebo effects, which is critical for regulatory acceptance in breast cancer neoadjuvant settings where pCR is the primary endpoint. This design flaw increases the risk of ambiguous or negative results that would fail to meet FDA requirements for accelerated approval, particularly since neoadjuvant breast cancer trials typically require randomized controls to establish causality. The absence of a comparator arm suggests Atossa may be prioritizing speed over rigorous evidence generation, potentially delaying regulatory pathways if the data are deemed insufficient for pivotal trials.
While RPD designations for DMD and MAS create theoretical PRV option value, the path to approval remains long and uncertain, with no clinical trial data yet published for either indication despite years of preclinical work. The DMD program faces steep challenges in demonstrating meaningful functional improvement in dystrophin-deficient models beyond biomarker signals, and the MAS indication involves complex endocrine dysregulation where historical trial failures for similar mechanisms raise skepticism about (Z)-endoxifen's efficacy. The $100–$205 million PRV valuation is contingent on successful approval—a distant and low-probability outcome for rare disease programs with high attrition rates—and cannot be relied upon as near-term value, especially given the company's ongoing cash burn ($9.6M net loss in Q1 2026) and declining cash position ($31.7M vs $41.3M at 2025 year-end).
Atossa's financial trajectory shows accelerating operating losses, with Q1 2026 net loss of $9.6M up 43% from Q1 2025 ($6.7M), driven by a 56% surge in G&A expenses primarily from professional fees ($3.8M vs $1.8M YoY), indicating potential inefficiencies or one-time costs not adequately explained in disclosures. Despite highlighting a "strong balance sheet," the company's cash reserves fell 23% quarter-over-quarter ($31.7M from $41.3M), and with no revenue and limited near-term catalysts, the current burn rate suggests less than 12 months of runway before needing dilutive financing. The lack of disclosed partnership discussions or licensing interest for (Z)-endoxifen across any indication raises concerns about external validation of its commercial potential, increasing the risk that Atossa must shoulder full development costs alone in a capital-intensive biotech environment.

Despite promising preclinical ESR1 mutation data, Atossa has not disclosed any clinical efficacy results for (Z)-endoxifen in endocrine-resistant breast cancer patients, creating significant uncertainty about translational success from preclinical models to human trials. The lack of updated clinical data from ongoing breast cancer studies (beyond the KARISMA prevention trial) raises concerns about whether the drug can achieve meaningful tumor shrinkage or PFS benefits in actual patients with resistant disease, especially given the high failure rate of endocrine therapies targeting ESR1 mutants. Without Phase 2 efficacy signals in the target resistant population, the bullish thesis relies on mechanistic plausibility rather than clinical proof, leaving the company vulnerable to negative trial outcomes that could invalidate the core oncology value proposition.
The EVANGELINE trial's open-label, single-arm Phase 2 design in neoadjuvant therapy lacks a control group, severely limiting the ability to attribute observed biological effects to (Z)-endoxifen plus goserelin versus natural history or placebo effects, which is critical for regulatory acceptance in breast cancer neoadjuvant settings where pCR is the primary endpoint. This design flaw increases the risk of ambiguous or negative results that would fail to meet FDA requirements for accelerated approval, particularly since neoadjuvant breast cancer trials typically require randomized controls to establish causality. The absence of a comparator arm suggests Atossa may be prioritizing speed over rigorous evidence generation, potentially delaying regulatory pathways if the data are deemed insufficient for pivotal trials.
While RPD designations for DMD and MAS create theoretical PRV option value, the path to approval remains long and uncertain, with no clinical trial data yet published for either indication despite years of preclinical work. The DMD program faces steep challenges in demonstrating meaningful functional improvement in dystrophin-deficient models beyond biomarker signals, and the MAS indication involves complex endocrine dysregulation where historical trial failures for similar mechanisms raise skepticism about (Z)-endoxifen's efficacy. The $100–$205 million PRV valuation is contingent on successful approval—a distant and low-probability outcome for rare disease programs with high attrition rates—and cannot be relied upon as near-term value, especially given the company's ongoing cash burn ($9.6M net loss in Q1 2026) and declining cash position ($31.7M vs $41.3M at 2025 year-end).
Atossa's financial trajectory shows accelerating operating losses, with Q1 2026 net loss of $9.6M up 43% from Q1 2025 ($6.7M), driven by a 56% surge in G&A expenses primarily from professional fees ($3.8M vs $1.8M YoY), indicating potential inefficiencies or one-time costs not adequately explained in disclosures. Despite highlighting a "strong balance sheet," the company's cash reserves fell 23% quarter-over-quarter ($31.7M from $41.3M), and with no revenue and limited near-term catalysts, the current burn rate suggests less than 12 months of runway before needing dilutive financing. The lack of disclosed partnership discussions or licensing interest for (Z)-endoxifen across any indication raises concerns about external validation of its commercial potential, increasing the risk that Atossa must shoulder full development costs alone in a capital-intensive biotech environment.

Peer group

Peer Comparison

Companies in the Pharmaceuticals

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	JNJ	Johnson & Johnson	primary	643.26 Bn	30.58	6.57	60.73 Bn
2	ABBV	AbbVie Inc.	primary	443.31 Bn	70.19	6.89	70.82 Bn
3	MRK	Merck & Co., Inc.	primary	364.74 Bn	115.10	5.48	53.91 Bn
4	NVS	Novartis Ag	primary	266.46 Bn	9.25	3.88	9.59 Bn
5	PFE	Pfizer Inc	primary	158.57 Bn	36.30	2.49	63.19 Bn
6	SNY	Sanofi	primary	52.33 Bn	11.23	0.98	25.19 Bn
7	RVMD	Revolution Medicines, Inc.	primary	43.79 Bn	-24.76	-	-
8	INCY	Incyte Corp	primary	25.23 Bn	15.65	4.34	0.04 Bn

Atossa Therapeutics ATOS

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password